Ritanserin,  (SID:461454364)

Chemical Name: 6-[2-[4-(bis(4-Fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one

CAS No.:87051-43-2

CAT No.: SRCR-001

It Is a novel chemical compound that has been gaining significant attention in the field of neuroscience and psychiatric research due to its potential therapeutic applications. This technical content will provide a comprehensive overview of it, its properties, mechanisms of action, and its role in current research, aimed at informing researchers, clinicians, and enthusiasts in the field.

Ritanserin Overview: Ritanserin is a serotonin receptor antagonist with a particular affinity for the serotonin 5-HT2A receptor subtype. It is part of a class of drugs known as atypical antipsychotics, which are primarily used to treat mental health disorders such as schizophrenia and bipolar disorder. However, researchers have been exploring its utility in a broader range of neurological and psychiatric conditions.

Mechanisms of Action: Ritanserin’s pharmacological profile revolves around its ability to modulate the serotonergic system. It acts as an antagonist, blocking the activation of serotonin receptors, primarily the 5-HT2A subtype. This action is believed to play a role in its therapeutic potential. By interfering with the serotonin pathway, Ritanserin can influence mood regulation, cognition, and behavior.

Potential Applications:

1. Antipsychotic Effects: Its’s primary use is in the management of psychotic disorders like schizophrenia. It has shown efficacy in reducing hallucinations, delusions, and thought disturbances, often associated with these conditions.
2. Mood Stabilization: Some studies have suggested that it may be beneficial in stabilizing mood, making it a potential treatment option for bipolar disorder patients.
3. Depression: Researchers are investigating Its’s antidepressant properties, as it may modulate the serotonin system, which is implicated in mood regulation.
4. Anxiety Disorders: Early research indicates that It may have anxiolytic effects, offering hope for the treatment of various anxiety disorders.
5. Cognitive Enhancement: There is growing interest in Its potential to enhance cognitive function, which may benefit individuals with cognitive impairments, including Alzheimer’s disease.

Current Research and Clinical Trials: The versatility of it  has sparked interest in its application across a spectrum of neurological and psychiatric conditions. Numerous preclinical and clinical trials are underway to further explore its potential therapeutic benefits. Researchers are also investigating its safety and potential side effects to gain a better understanding of its overall risk-benefit profile.

It also known by its developmental code name R-55667, is a serotonin antagonist medication described as an anxiolytic, antidepressant, antiparkinsonian agent, and antihypertensive agent^] It was chiefly investigated as a drug to treat insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant 5HT2a and 5HT2c antagonism

It was never marketed for medical use due to safety problems but is currently used in scientific research.

Some of the safety liabilities that lead to its discontinuation for the treatment of insomnia has led to its potential repurposing in the field of oncology. Specifically, ritanserin acts as a potent inhibitor of diacylglycerol kinase alpha (DGKα). As such, it may be used to treat certain types of glioblastoma and melanoma. It has also been used as a reference compound to identify putatively more selective and potent DGKα inhibitors to treat these forms of cancer as well as possibly others.

Additionally, ritanserin blocks c-RAF activation and induces apoptotic cell death of non–small cell lung cancer and small cell lung cancer cells.

Chemical Synthesis:

Aminothiazole (2-thiazolamine)  is condensed with 2-acetylbutyrolactone [517-23-7] under DS-trap until the water has separated. Condensation of this β-keto lactone can be visualized to involve initial attack on the reactive butyrolactone by the primary nitrogen; cyclodehydration of that hypothetical intermediate  gives 6-(2-hydroxyethyl)-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one  Halogenation of the terminal alcohol with phosphorus oxychloride then yields 6-(2-chloroethyl)- 7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, [86488-00-8] (5). Alkylation with 4-(bis(4-fluorophenyl)methylene)piperidine, [58113-36-3] would complete the synthesis of ritanserin